Amivantamab (Jnj-61186372), An Anti-Egfr-Met Bispecific Antibody, In Patients With Egfr Exon 20 Insertion (Exon20ins)-Mutated Non-Small Cell Lung Cancer (Nsclc).

Keunchil Park,Thomas John,Sang-We Kim,Jong Seok Lee,Catherine A. Shu,Dong-Wan Kim,Santiago Viteri Ramirez,Alexander I. Spira,Joshua K. Sabari,Ji-Youn Han,Jose Manuel Trigo,Chee Khoon Lee,Ki Hyeong Lee,Nicolas Girard, Patricia A Lorenzini,John Xie,Amy Roshak,Meena Thayu,Roland Elmar Knoblauch,Byoung Chul Cho

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 66|浏览20

暂无评分

摘要

9512Background: EGFR exon20ins-mutated NSCLC is generally refractory to EGFR tyrosine kinase inhibitors (TKIs) and is associated with poor prognosis. Amivantamab (JNJ-61186372) is a novel, fully hu...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要